Loading...
•
Dec 31, 2021
Eli Lilly Q4 2021 Earnings Report
Lilly experienced growth and pipeline success, driven by volume and key growth products, despite pandemic-related challenges.
Key Takeaways
Eli Lilly reported an 8% increase in revenue for Q4 2021, driven by an 11% increase in volume. Excluding COVID-19 antibodies, revenue grew by 6%. EPS decreased by 18% to $1.90 on a reported basis but increased by 8% to $2.49 on a non-GAAP basis. The company reaffirmed its 2022 EPS guidance.
Revenue in Q4 2021 increased 8 percent, driven by volume growth of 11 percent.
Excluding COVID-19 antibodies, fourth-quarter 2021 revenue grew 6 percent.
Key growth products contributed 14 percentage points of revenue growth and represented 61 percent of total revenue in Q4 2021, excluding revenue from COVID-19 antibodies.
Fourth-quarter 2021 EPS decreased 18 percent to $1.90 on a reported basis and increased 8 percent to $2.49 on a non-GAAP basis.
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Verzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comOutside U.S. Revenue
CapyFin.com Forward Guidance
The company has reaffirmed all elements of its 2022 financial guidance. EPS for 2022 are still expected to be in the range of $8.00 to $8.15 on a reported basis and $8.50 to $8.65 on a non-GAAP basis.